AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05339100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accessorized Pre-Filled Syringe
Description: Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
Study NCT06261892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collect HPV DNA from urine
Description: Use a sample collector to collect urine
Study NCT05426005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
Study NCT05547464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT164a1
Description: Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
Study NCT05547464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT164b1
Description: Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
Study NCT05547464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05885464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEAM-201
Description: A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
Study NCT05434650 — intervention group
Intervention type: DEVICE
Intervention: electrophysiology study and ablation with an Abbott Ablation Catheter
Description: During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
Study NCT06261229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The participant will consume food about/ within 8-hour per day
Study NCT06261229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting + Behavioral economic
Description: The participant will consume food about/ within 8-hour per day. They will be received a reward as money when achieve weight loss goal or/and success doing intermittent fasting 5 days/week
Study NCT06261229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Modification
Description: Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
Study NCT04751578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPEDE-FX Embolization Plug
Description: Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
Study NCT06639204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.
Study NCT06639204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment without acceleration
Description: No additional appliances will be used. Only the traditional fixed appliances (braces).
Study NCT06645457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Patients squeeze the stress ball
Study NCT06645457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing technique
Description: breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
Study NCT06275724 — intervention group
Intervention type: OTHER
Intervention: inclisiran
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
Study NCT05146596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use low level light therapy,The Dr.Tai's energy cap
Description: 30 minutes each time, three times a week, a total of 12 times.
Study NCT06148090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clobetasol decreasing measurement
Description: At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month
Study NCT05575414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic dietary sessions
Description: Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
Study NCT05575414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Tool
Description: The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
Study NCT05083598 — intervention group
Intervention type: OTHER
Intervention: 6 Minute walking test
Description: The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.
Study NCT05083598 — intervention group
Intervention type: OTHER
Intervention: Frailty questionaires
Description: Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
Study NCT06424145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Superior radial artery
Description: Upper radial artery, 1 ml of lidocaine
Study NCT06424145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right side of radial artery
Description: Right side of the radial artery,1ml of lidocaine
Study NCT05422573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post-test cardiovascular genetic counseling with pre-test education by video
Description: post-test cardiovascular genetic counseling with pre-test education by video
Study NCT05422573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: required phone call with genetic counselor pre-test
Description: REQUIRED phone call with genetic counselor pre-test.
Study NCT05422573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: optional phone call with genetic counselor pre-test
Description: OPTIONAL phone call with genetic counselor pre-test
Study NCT05213390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dora
Description: DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
Study NCT06113237 — intervention group
Intervention type: DRUG
Intervention: Epidiolex
Description: Oral solution
Study NCT06096740 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms.
Study NCT06096740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms.
Study NCT05169554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.
Description: Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
Study NCT05169554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.
Description: On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily.
Study NCT04734665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib-Bevacizumab
Description: Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Study NCT04922424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
Study NCT04922424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
Study NCT04509180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Endovascular approach
Study NCT04509180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Convergent procedure
Description: Surgical and endovascular approach
Study NCT04702178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2
Study NCT04702178 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo
Study NCT06547944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg bid/d, from C1 to CR and MRD-negative or C24
Study NCT06547944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24
Study NCT06547944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
Study NCT05319665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-mounted display
Description: The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
Study NCT04915352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal provocation test - 725 Dermatophagoides Pteronyssinus
Description: 3 different concentrations of Nasal Provocation Test are administered to patients:~* Nasal spray at 50 SBE/ml for 36 months~* Nasal spray at 500 SBE/ml for 36 months~* Nasal spray at 5000 SBE/ml for 36 months
Study NCT04915352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative control
Description: Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
Study NCT05562310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN). This is total nutrition provided by central vein.
Description: phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
Study NCT05078138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
Study NCT05507619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture with Heat Therapy + Standard Care
Description: Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
Study NCT05507619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
Study NCT05317078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 794
Description: Short-term intravenous (IV) infusion.
Study NCT05575180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide 250Mg Tab
Description: Oral acetazolamide
Study NCT05575180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide Pill
Description: Oral Methazolamide
Study NCT05575180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT05867576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations.
Study NCT05192330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
Study NCT05192330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
Study NCT05778513 — intervention group
Intervention type: OTHER
Intervention: Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program
Description: Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks
Study NCT05778513 — intervention group
Intervention type: OTHER
Intervention: Passive knee flexion-extension + Cycle ergometer exercise
Description: Passive knee flexion-extension movements + Incremental cycle ergometer exercise
Study NCT01872546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUMIRA 40mg
Study NCT06329947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib 250mg/d qd once daily
Description: mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
Study NCT05108571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/1000mg
Description: single dose administration (one tablet once a day)
Study NCT05108571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/1000mg
Description: single dose administration (one tablet once a day)
Study NCT06368037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFire Transcatheter Myocardial Radiofrequency Ablation System
Description: The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
Study NCT06032533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning with Automatic Tourniquet Device
Description: 5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment.
Study NCT06032533 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning with Automatic Tourniquet Device
Description: 5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment.
Study NCT05627141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation; Cryotherapy, Massage
Description: Photobiomodulation: the 20 participants will receive active photobiomodulation or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session. Cryotherapy combined with compression: the 20 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression, or sham (25°C for 20 min) combined with light compression, on the lower limbs, immediately after the protocol. induction of muscle damage and fatigue. Effective cryotherapy or sham will be applied in a randomized and crossover manner, with an interval of 15 days between each evaluation session.~Massage: the 20 participants will receive the effective massage or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.